Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Min-Hee Ryu & Yoon-Koo Kang. (2009) ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer. Expert Review of Anticancer Therapy 9:12, pages 1745-1751.
Read now
Read now
Anthony B. El-Khoueiry & Heinz-Josef Lenz. (2006) Should Continuous Infusion 5-Fluorouracil Become the Standard of Care in the USA as It Is in Europe?. Cancer Investigation 24:1, pages 50-55.
Read now
Read now
Cynthia Gail Leichman. (1994) Prolonged Infusion of Fluorinated Pyrimidines in Gastrointestinal Malignancies: A Review of Recent Clinical Trials. Cancer Investigation 12:2, pages 166-175.
Read now
Read now
Thomas Spector. (1993) 5-Ethynyluracil (776C85): an inactivator of uracil reductase that potentiates the antitumour activity of 5-fluorouracil. Current Opinion on Therapeutic Patents 3:12, pages 1751-1754.
Read now
Read now
Articles from other publishers (35)
Rafael C. Coelho, Pedro D.P. Abreu, Mariana R. Monteiro, Ana Paula Stramosk, Alvaro Henrique I. Garces, Andreia Cristina Melo, Marcia S. Graudenz & Carlos Jose C. Andrade. (2019) Cisplatin, Fluorouracil in Bolus Injection, and Leucovorin in First-Line Therapy for Advanced Gastric Cancer as an Alternative to Protocols With Infusional Fluorouracil. Journal of Global Oncology:5, pages 1-8.
Crossref
Crossref
Herbert HurwitzEdith P. MitchellThomas CartwrightAmbrose KwokSylvia HuEdward McKennaYehuda Z. Patt. (2012) A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard). The Oncologist 17:7, pages 937-946.
Crossref
Crossref
Jianguo Zhi, Eric Chen, Pierre Major, Ivon Burns, Bridget Robinson, Joe McKendrick, Karen Rittweger, Markus Abt & David Goldstein. (2011) A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology 68:5, pages 1199-1206.
Crossref
Crossref
Daniel G. HallerJim CassidyStephen J. ClarkeDavid CunninghamEric Van CutsemPaulo M. HoffMace L. RothenbergLeonard B. SaltzHans-Joachim SchmollCarmen AllegraJoseph R. BertinoJean-Yves DouillardBengt G. GustavssonGerard MilanoMichael O'ConnellYoucef RustumJosep TaberneroFrank GilbergFlorin SirzénChris Twelves. (2008) Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines. Journal of Clinical Oncology 26:13, pages 2118-2123.
Crossref
Crossref
C. Porta, C. Paglino, I. Imarisio & L. Bonomi. (2008) Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clinical and Experimental Medicine 7:4, pages 127-134.
Crossref
Crossref
Ikuo Takahashi, Yasunori Emi, Yoshihiro Kakeji, Junji Uchida, Masakazu Fukushima & Yoshihiko Maehara. (2005) Increased Antitumor Activity in Combined Treatment TS-1 and Docetaxel. Oncology 68:2-3, pages 130-137.
Crossref
Crossref
M.P Decatris, S Sundar & K.J O’Byrne. (2004) Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treatment Reviews 30:1, pages 53-81.
Crossref
Crossref
Anne-Renee Hartman, Amy Grekowicz, Bert L. Lum, Robert W. Carlson, Christine Schurman, Branimir I. Sikic, Richard Shapiro & Frank E. Stockdale. (2003) Phase I Trial of Uracil–Ftorafur, Leucovorin, and Etoposide: An Active All-oral Regimen for Metastatic Breast Cancer. Breast Cancer Research and Treatment 82:1, pages 61-69.
Crossref
Crossref
Ikuo Takahashi, Yoshihiro Kakeji, Yasunori Emi, Masato Sakurai, Yusuke Yonemura, Yasue Kimura & Yoshihiko Maehara. (2003) S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects. Gastric Cancer 6:S1, pages 28-33.
Crossref
Crossref
A.B. BensonIIIIII, E. Mitchell, N. Abramson, B. Klencke, P. Ritch, J.P. Burnham, C. McGuirt, T. Bonny, J. Levin & J. Hohneker. (2002) Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Annals of Oncology 13:4, pages 576-581.
Crossref
Crossref
Miguel Martín. (2001) Platinum Compounds in the Treatment of Advanced Breast Cancer. Clinical Breast Cancer 2:3, pages 190-208.
Crossref
Crossref
Laura Mascia & Piero Luigi Ipata. (2001) Activation pathways of 5-fluorouracil in rat organs and in PC12 cells11Abbreviations: PRPP, 5-phosphoribosyl 1-pyrophosphate; 5-FU, 5-fluorouracil; FUrd, 5-fluorouridine; 5-FUMP, 5-FUDP, and 5-FUTP, 5-fluorouridine 5′-mono-, -di-, and -triphosphate, 5-Fdeoxyuridine, 5-fluoro-2′-deoxyuridine; 5-FdeoxyUMP, 5-FdeoxyUDP, and 5-FdeoxyUTP, 5-fluoro-2′-deoxyuridine 5′-mono-, -di-, and triphosphate; Rib1-P, ribose 1-phosphate; and deoxyRib1-P, 2′-deoxyribose 1-phosphate.. Biochemical Pharmacology 62:2, pages 213-218.
Crossref
Crossref
Chris H Takimoto. (2001) The clinical pharmacology of the oral fluoropyrimidines. Current Problems in Cancer 25:3, pages 134-213.
Crossref
Crossref
Bruce D. Minsky. (2001) UFT� plus oral leucovorin calcium (Orzel?) and radiation in combined modality therapy: A comprehensive review. International Journal of Cancer 96:1, pages 1-10.
Crossref
Crossref
F. Nolè, E. Munzone, M. Mandalà, C. Catania, L. Orlando, M.G. Zampino, I. Minchella, M. Colleoni, G. Peruzzotti, E. Marrocco & A. Goldhirsch. (2001) Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study. Annals of Oncology 12:1, pages 95-100.
Crossref
Crossref
A. Hügli, A.-P. Sappino, S. Anchisi, B. Mermillod, P. Schafer, J.L. Anguenot & H. Bonnefoi. (2000) Infusional ECarboF in patients with advanced breast cancer: A very active and well-tolerated out-patient regimen. Annals of Oncology 11:12, pages 1557-1561.
Crossref
Crossref
J. NemunaitisR. EagerT. TwaddellA. CoreyK. SekarK. TkaczukJ. ThompsonP.M. HoffR. Pazdur. (2000) Phase I Assessment of the Pharmacokinetics, Metabolism, and Safety of Emitefur in Patients With Refractory Solid Tumors. Journal of Clinical Oncology 18:19, pages 3423-3434.
Crossref
Crossref
A. Zambelli, F.S. Robustelli della Cuna, L. Ponchio, G. Ucci, G.A. Da Prada & G. Robustelli della Cuna. (2000) Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer. Breast Cancer Research and Treatment 61:3, pages 241-247.
Crossref
Crossref
Gamini S. Soori, Robert K. Oldham, Tracy W. Dobbs, Martin J. Bury, Curtis K. Church & Carol DePriest. (2000) Chemo-Biotherapy with 5-Fluorouracil, Leucovorin, and Alpha Interferon in Metastatic Carcinoma of the Colon - A Cancer Biotherapy Research Group [CBRG] Phase II Study. Cancer Biotherapy and Radiopharmaceuticals 15:2, pages 175-183.
Crossref
Crossref
Dolores Gallardo-Rinc�n, Luis F. O�ate-Oca�a & Germ�n Calderillo-Ruiz. (2000) Neoadjuvant Chemotherapy With P-ELF (Cisplatin, Etoposide, Leucovorin, 5-Fluorouracil) Followed by Radical Resection in Patients With Initially Unresectable Gastric Adenocarcinoma: A Phase II Study. Annals of Surgical Oncology 7:1, pages 45-50.
Crossref
Crossref
Omer Kucuk, Kishan J. Pandya, Roland T. Skeel, Howard Hochster & Martin D. Abeloff. (1999) Phase II study of cisplatin and 5‐fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). Breast Cancer Research and Treatment 57:2, pages 201-206.
Crossref
Crossref
Toshifusa Nakajima, Keiichiro Ohta, Shou Ishihara, Shigekazu Ohyama, Mitsumasa Nishi, Yasuhiko Ohashi, Akio Yanagisawa & Yo Kato. 1999. Multimodality Therapy for Gastric Cancer. Multimodality Therapy for Gastric Cancer
97
103
.
F. deBraud, E. Munzone, F. Nolè, T. De Pas, R. Biffi, S. Brienza & M. S. Aapro. (1998) Synergistic Activity of Oxaliplatin and 5-Fluorouracil in Patients With Metastatic Colorectal Cancer With Progressive Disease While on or After 5-Fluorouracil. American Journal of Clinical Oncology 21:3, pages 279-283.
Crossref
Crossref
Peter J. O’Dwyer & James P. Stevenson. 1998. Gastrointestinal Oncology. Gastrointestinal Oncology
111
152
.
M. Zambetti, R. Demicheli, D. De Candis, G. Antonelli, A. Giacobone, M. Terenziani, A. Laffranchi, F. Garbagnati, S. Biasi & G. Bonadonna. (1997) Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. Breast Cancer Research and Treatment 44:3, pages 255-260.
Crossref
Crossref
Martine Piccart. (1997) New cytotoxic agents. Cancer Treatment Reviews 23, pages S59-S67.
Crossref
Crossref
Marco Colleoni, Giovanni Vicario, Patrizia Nelli, Gigliola Sgarbossa, Francesca Pancheri & Paolo Manente. (2018) Intermittent Continuous Infusion of Fluorouracil and Low-Dose Oral Leucovorin in Pretreated Breast Cancer: A Pilot Study. Tumori Journal 83:3, pages 665-668.
Crossref
Crossref
Toshifusa Nakajima, Keiichiro Ota, Shou Ishihara, Shigekazu Oyama, Mitsumasa Nishi, Yasuhiko Ohashi & Akio Yanagisawa. (1997) Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Annals of Surgical Oncology 4:3, pages 203-208.
Crossref
Crossref
Michael A. Carducci, Ross A. Abrams, Charles J. Yeo, Ralph H. Hruban, Marianna L. Zahurak, John L. Cameron & Louise B. Grochow. (1996) Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy. International Journal of Radiation Oncology*Biology*Physics 35:1, pages 143-150.
Crossref
Crossref
D. Bissett, S.B. Kaye, G. Baxter & J. Moss. (1996) Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy. Clinical Oncology 8:4, pages 247-249.
Crossref
Crossref
Stephen T. Davis, Suzanne S. Joyner, David P. Baccanari & Thomas Spector. (1994) 5-Ethynyluracil (776C85): Protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochemical Pharmacology 48:2, pages 233-236.
Crossref
Crossref
J. Cassidy. (1994) Chemotherapy administration: Doses, infusions and choice of schedule. Annals of Oncology 5, pages S25-S30.
Crossref
Crossref
S.M. Swain & L.N. Harris. (1994) Can we increase survival in breast cancer with innovative applications of conventional drugs?. European Journal of Cancer 30:4, pages 423-424.
Crossref
Crossref
Sheldon Fine, Charles Erlichman, Leonard Kaizer, David Warr & Tahany Gadalla. (1994) Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer. Breast Cancer Research and Treatment 30:2, pages 205-209.
Crossref
Crossref
Jean L. Grem, Nanette McAtee, Frank Balis, Robert Murphy, David Venzon, Barnett Kramer, Barry Goldspiel, Martin Begley & Carmen J. Allegra. (1993) A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer 72:3, pages 663-668.
Crossref
Crossref